Your search for tofacitinib returned 15 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Post remove
MPR First Report remove

Your search for tofacitinib returned 15 results

Sort Results:

Relevant Recent
AIBD 2019

Tofacitinib vs Vedolizumab: Short-Term Efficacy Compared in Ulcerative Colitis

In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
AIBD 2019

Impact of Tofacitinib on Extraintestinal Symptoms in UC Patients Examined

Treatment with tofacitinib appears to have little impact on extraintestinal manifestations (EIMs) in patients with moderate to severe ulcerative colitis (UC) and might even improve them, according to an analysis of the OCTAVE program. Findings were presented at the 2019 AIBD Annual Meeting in Orlando, Florida.
ACR/ARHP Annual Meeting 2013

Twice-Daily Tofacitinib Shows Sustained Efficacy Over 5 Years in RA

Tofacitinib 5mg or 10mg twice daily showed a consistent safety profile and sustained efficacy over 5 years in long-term extension studies for patients with rheumatoid arthritis, as presented at the 2013 ACR/ARHP Annual Meeting.